Adherence to anti-diabetic drug therapy and self management practices among type-2 diabetics in Nigeria.
OBJECTIVE
To describe the pattern of anti-diabetic drug prescribing; ascertain the level of glycemic control, adherence with prescribed anti-diabetic medications, and diabetes self management practices among patients with type-2 diabetes in a tertiary care setting in Nigeria.


METHODS
University College Hospital (UCH); a 900 bed teaching hospital with medical residents located in Ibadan, southwestern Nigeria.


METHODS
The study consisted of two phases. A cross-sectional review of randomly selected 200 case notes of type 2 diabetic patients that attended the Endocrinology clinic over 3 month; and crosssectional interviews, with a pre-tested Adherence and Self-Management Monitoring Tool (ASMMT), of 200 consecutive patients that presented their drug prescriptions at the satellite pharmacy unit over a 4 week period at a 900-bed teaching hospital located in Ibadan, South-Western Nigeria.


RESULTS
Oral Hypoglycemic Agents (OHA) were prescribed for 86% (171) of cohorts while insulin and OHA was prescribed in 14% (29). About 70.8% (121) of patients on OHA were on combination therapy. The most frequently prescribed OHA combination was glibenclamide and metformin (95.8%). Glibenclamide was prescribed as twice daily regimen in 69% of cohorts. The most frequently documented side effect was hypoglycemia (60.3%). Only 44% (88) of cohorts had adequate glycemic control; of these, 93% (82) were adjudged adherent with prescribed anti-diabetic drugs. Interviews with the structured ASMMT revealed that 59% of patients were non-adherent with the previous anti-diabetic drugs due to lack of finance (51.7%); side effects (34.5%); perceived inefficacy of prescribed anti-diabetic drugs leading to self-medication with local herbs (13.8%). Only 20% of non-adherent patients claimed disclosure to physicians during consultation. The identified factors for non-disclosure were lack of privacy during consultation (58%); and short consultation time (42%). The knowledge and practice of critical components of diabetes self-management behaviours were generally low among the cohort studied. However, it was significantly higher among patient judged adherent with their prescribed anti-diabetic medications (P < 0.05).


CONCLUSIONS
Majority of patients with type 2 diabetes in an ambulatory tertiary care setting in Nigeria are managed with OHA combinations, mainly glibenclamide and metformin. While the current prescribing strategy achieved glycemic control in about one third of patients, majority are still not meeting the recommended blood glucose targets due to poor adherence with prescribed drug regimen, and poor knowledge and practice of successful self-management.
Yusuff
Kazeem B
KB
Department of Clinical Pharmacy & Pharmacy Administration, Faculty of Pharmacy, University of Ibadan, Ibadan, Nigeria. yusuffkby@yahoo.co.uk
Obe
Olubunmi
O
Joseph
Bonatson Y
BY
D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D001786:Blood Glucose / Q000187:drug effects; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D003625:Data Collection; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D007722:Health Knowledge, Attitudes, Practice; D006785:Hospitals, University / Q000706:statistics & numerical data; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009549:Nigeria / Q000453:epidemiology; D008517:Phytotherapy; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data; D012648:Self Care / Q000706:statistics & numerical data*; D016903:Drug Monitoring
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin
Postgrad Med J. 1999 Oct;75(888):603-6
10621901
Ann Intern Med. 1999 Aug 17;131(4):281-303
10454950
JAMA. 1999 Jun 2;281(21):2005-12
10359389
Diabetes Care. 2001 Apr;24(4):683-9
11315831
JAMA. 2002 May 15;287(19):2570-81
12020339
Diabetes Care. 2005 Jul;28(7):1599-603
15983307
Clin Ther. 2002 Mar;24(3):460-7
11952029
Endocrinol Metab Clin North Am. 1989 Mar;18(1):163-83
2645125
Diabetes Res Clin Pract. 2000 Aug;49(2-3):93-9
10963819
Diabetes Care. 1997 Apr;20(4):556-61
9096980
West Afr J Med. 2004 Jul-Sep;23(3):232-5
15587836
Am J Health Syst Pharm. 2002 Dec 1;59 Suppl 9:S18-21
12489383
Diabetes Metab Res Rev. 2000 Sep-Oct;16 Suppl 1:S70-4
11054893
Diabetes Care. 2004 Jan;27(1):17-20
14693960
Nature. 2001 Dec 13;414(6865):782-7
11742409
J Hypertens. 2005 Jun;23(6):1261-6
15894903
Lancet. 1998 Sep 12;352(9131):837-53
9742976
Drug Saf. 2000 Apr;22(4):313-20
10789825
JAMA. 1996 Nov 6;276(17):1409-15
8892716
BMJ. 2006 Jan 14;332(7533):73-8
16371403
Diabetes Care. 1998 Apr;21(4):501-5
9571331
Diabetes Care. 2005 Jul;28(7):1611-7
15983309
Lancet. 1998 Sep 12;352(9131):854-65
9742977
N Engl J Med. 1998 Jul 23;339(4):229-34
9673301
Diabetes Care. 2003 Jun;26(6):1847-51
12766121
Niger J Med. 2003 Oct-Dec;12(4):193-7
14768192
Afr J Med Med Sci. 2005 Jun;34(2):133-40
16749337
Med J Malaysia. 2004 Aug;59(3):411-7
15727390
Afr J Med Med Sci. 2005 Dec;34(4):389-94
16752671
Diabet Med. 2002 Dec;19(12):978-85
12647837
Cent Afr J Med. 1994 Oct;40(10):286-9
7828181
Diabet Med. 2002 Aug;19(8):673-80
12147149
Eur J Endocrinol. 2004 Oct;151 Suppl 2:T3-7; discussion T29-30
15487977
West Afr J Med. 2003 Jun;22(2):152-5
14529227
West Afr J Med. 2003 Jun;22(2):161-3
14529229
Diabetes Care. 1998 Sep;21(9):1414-31
9727886
Diabetes Care. 2004 Oct;27(10):2444-9
15451914